Answer
Rifampicin, a strong CYP3A4 inducer, at 600 mg once daily decreased fedratinib (Inrebic) exposure (AUCinf) by approximately 80% when co-administered with a single 500 mg fedratinib dose.
Sources for this answer
- Inrebic 100 mg hard capsulesBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §4.5 Interaction with other medicinal products · Version 9Document updated
Sources checked